General Information of Drug (ID: DMZW50O)

Drug Name
Debio 1347 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Breast cancer 2C60-2C65 Phase 1/2 [2]
Cross-matching ID
PubChem CID
66555680
CAS Number
CAS 1265229-25-1
TTD Drug ID
DMZW50O

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Erdafitinib DMI782S Bladder cancer 2C94 Approved [4]
Futibatinib DMWM4D0 Intrahepatic cholangiocarcinoma 2C12.10 Approved [5]
Infigratinib DMNKBEC Cholangiocarcinoma 2C12.10 Approved [2]
HIF-1alpha DM4OQRD Lymphoma 2A80-2A86 Phase 4 [6]
ARQ-087 DM02BVQ Intrahepatic cholangiocarcinoma 2C12.10 Phase 3 [2]
AZD4547 DM3827C Solid tumour/cancer 2A00-2F9Z Phase 2/3 [2]
BAY1163877 DMCSGJ2 Bladder cancer 2C94 Phase 2 [7]
ICP-192 DM524GR Bladder cancer 2C94 Phase 2 [8]
PRN1371 DMR7BAO Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PD173074 DMP0N4U Nasopharyngeal carcinoma 2B6B Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [9]
Intedanib DMSTA36 Colorectal cancer 2B91.Z Approved [10]
Pemigatinib DM819JF Cholangiocarcinoma 2C12.10 Approved [11]
Infigratinib DMNKBEC Cholangiocarcinoma 2C12.10 Approved [12]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [13]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [14]
ARQ-087 DM02BVQ Intrahepatic cholangiocarcinoma 2C12.10 Phase 3 [15]
AZD4547 DM3827C Solid tumour/cancer 2A00-2F9Z Phase 2/3 [16]
AM-001 DMGVQI8 Actinic keratosis EK90.0 Phase 2 [17]
FGF-1 DMXMC8I Coronary heart disease BA80.Z Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pemigatinib DM819JF Cholangiocarcinoma 2C12.10 Approved [11]
Interferon Alfa-2a, Recombinant DMUTZ8S Chronic HCV-1 infection 1E51.1 Approved [19]
Palifermin DM9JOYP Oral mucositis DA01.11 Approved [20]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [13]
Trafermin DMLKI2B Periodontitis DA0C Phase 3 [21]
LY2874455 DMZ0DMY Solid tumour/cancer 2A00-2F9Z Phase 2 [22]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [23]
AEE-788 DMEOS5K Solid tumour/cancer 2A00-2F9Z Phase 1/2 [24]
BAY1179470 DM7L91K Solid tumour/cancer 2A00-2F9Z Phase 1 [25]
Alofanib DMIEKTF Gastric adenocarcinoma 2B72 Phase 1 [26]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pemigatinib DM819JF Cholangiocarcinoma 2C12.10 Approved [11]
Trapidil DMY67U8 Acute coronary syndrome BA41 Phase 4 [27]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [13]
TKI258 DMYLT67 Renal cell carcinoma 2C90 Phase 3 [24]
BMS-582664 DMDAN8H Hepatocellular carcinoma 2C12.02 Phase 3 [24]
B-701 DMOMDA4 Bladder cancer 2C94 Phase 2 [28]
Recifercept DML8N3Y Achondroplasia LD24.00 Phase 2 [29]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [23]
AEE-788 DMEOS5K Solid tumour/cancer 2A00-2F9Z Phase 1/2 [24]
Anti-FGFR3 DM6QENU Multiple myeloma 2A83 Phase 1 [30]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor (FGFR) TT0LF7H NOUNIPROTAC Modulator [3]
Fibroblast growth factor receptor 1 (FGFR1) TTRLW2X FGFR1_HUMAN Inhibitor [2]
Fibroblast growth factor receptor 2 (FGFR2) TTGJVQM FGFR2_HUMAN Inhibitor [2]
Fibroblast growth factor receptor 3 (FGFR3) TTST7KB FGFR3_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03834220) Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5 TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
6 Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
7 Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
8 Clinical pipeline report, company report or official report of InnoCare Pharma.
9 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
10 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
12 Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
13 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
14 Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
16 AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
17 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
18 Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002 Jun 17;86(12):1864-70.
19 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
20 Keratinocyte growth factor. Expert Opin Biol Ther. 2009 Jun;9(6):779-87.
21 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
22 Company report (Eli Lilly) (drug: LY2874455)
23 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
24 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
25 National Cancer Institute Drug Dictionary (drug id 751593).
26 Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28]. Eur J Cancer. 2017 Jan;70:156.
27 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
28 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
29 In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.
30 Clinical pipeline report, company report or official report of Genentech (2011).